![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Stangel Martin
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.13, Iss.4, 2004-04, pp. : 331-347
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Oral Disease-Modifying Treatments for Multiple Sclerosis: The Story So Far
CNS Drugs, Vol. 21, Iss. 6, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Disease Modifying Treatments for Multiple Sclerosis: What is on the Horizon?
CNS Drugs, Vol. 11, Iss. 2, 1999-02 ,pp. :